Page last updated: 2024-11-12
ro 48-6791
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
ID Source | ID |
---|---|
PubMed CID | 9953485 |
SCHEMBL ID | 7394354 |
MeSH ID | M0272975 |
Synonyms (15)
Synonym |
---|
ro 48-6791 |
ro-48-6791 |
unii-nke9773pbb |
172407-17-9 |
nke9773pbb , |
SCHEMBL7394354 |
AKOS027338649 |
ro48-6791 |
3-[5-[(dipropylamino)methyl]-1,2,4-oxadiazol-3-yl]-8-fluoro-5-methyl-4h-imidazo[1,5-a][1,4]benzodiazepin-6-one |
3-{5-[(dipropylamino)methyl]-1,2,4-oxadiazol-3-yl}-8-fluoro-5-methyl-4,5-dihydro-6h-imidazo[1,5-a][1,4]benzodiazepin-6-one |
DTXSID10938143 |
6h-imidazo(1,5-a)(1,4)benzodiazepin-6-one, 3-(5-((dipropylamino)methyl)-1,2,4-oxadiazol-3-yl)-8-fluoro-4,5-dihydro-5-methyl- |
3-(5-dipropylaminomethyl-(1,2,4)oxadiazol-3-yl)-8-fluoro-5-methyl-5,6-dihydro-4h-imidazo(1,5-a)(1,4)benzodiazepin-6-one |
Q7339202 |
A907544 |
Research Excerpts
Pharmacokinetics
Ro 48-6792 showed a considerably longer half-life than the parent compound. Pharmacokinetic variables of Ro 48- 6791 were similar for both groups.
Compound-Compound Interactions
Excerpt | Reference | Relevance |
---|---|---|
"In this randomized, double-blinded study, we compared the onset and recovery characteristics of an investigational benzodiazepine, Ro 48-6791 (when administered alone or combined with meperidine), a midazolam-meperidine combination for sedation during gastrointestinal (GI) endoscopic procedures." | ( Comparison of the sedation and recovery profiles of Ro 48-6791, a new benzodiazepine, and midazolam in combination with meperidine for outpatient endoscopic procedures. Gold, J; Gold, M; Tang, J; Wang, B; White, PF, 1999) | 0.76 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (9)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 8 (88.89) | 18.2507 |
2000's | 1 (11.11) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.53
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.53) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 4 (44.44%) | 5.53% |
Reviews | 1 (11.11%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 4 (44.44%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |